Groundbreaking New Product Launch Planned for September 2008
PLYMOUTH MEETING, Pa., May 27 /Xinhua-PRNewswire-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: BJGP) (''BMP Sunstone'' or the ''Company'') today announced that it has received an Import Drug License (IDL) from the SFDA to market a new Propess applicator in China.
Prior to today in China, Propess was indicated for cervix dilation to help induce labor, and is currently distributed via vaginal inserts that are 1.1 mm thick. The birth rate in China averages approximately 1.2%, which results in about 16 million births each year. Further, about 18% of pregnant women require cervical dilation, including 3% of women with Premature Rupture of Membranes (PROM).
The IDL approved today will enable BMP Sunstone to market and distribute Propess vaginal inserts that are 0.8mm thick. The new applicator improves efficacy and broadens the potential use of Propess to women with PROM. The Company estimates that the 0.8mm Propess will increase the number of targeted women with PROM by approximately 500,000, or 3% of all pregnant women in China.
Cytokine PharmaScience Inc, the licensor, is in the process of applying for a new brand name for the 0.8 mm insert. Propess has been adopted as the first line treatment by China OB association. The Company anticipates distributing the 0.8mm Propess by September 2008.
David Gao, Chief Executive Officer of BMP Sunstone, stated, "We are
pleased to offer this new form of Propess. The 1.1mm Propess insert has
been extremely popular in China, evidenced by usage in our 500-plus
hospital network. We anticipate that the 0.8mm Propess will help us to
expand our distribution network to 1000 hospitals by 2010, and cover more
|SOURCE BMP Sunstone Corporation|
Copyright©2008 PR Newswire.
All rights reserved